In the study presented, we approached the expression of both ADAMs immunohistochemically and revealed a moderate to high ADAM17 and a distinctly weaker ADAM10 protein expression in RB patients’ tumor sections. This evidence concerns the gene ADAM17 and retinoblastoma.